Nandrolone Decanoate-Induced Prostatic Hyperplasia: A Histopathological Study

Lone, Parvaiz Ahmad; Khan, Mudasir Ahmad; Shah, Bashir Ahmad

doi:10.61882/rabms.11.3.285

Volume 11, Issue 3 (8-2025) Journal of Research in Applied and Basic Medical Sciences 2025, 11(3): 285-289 | Back to browse issues page

‎ 10.61882/rabms.11.3.285

Ethics code: MC-421 (GMCS-2020)

Mendeley

Zotero

RefWorks

Lone P A, Khan M A, Shah B A. Nandrolone Decanoate-Induced Prostatic Hyperplasia: A Histopathological Study. Journal of Research in Applied and Basic Medical Sciences 2025; 11 (3) :285-289
URL: http://ijrabms.umsu.ac.ir/article-1-427-en.html

Nandrolone Decanoate-Induced Prostatic Hyperplasia: A Histopathological Study

Parvaiz Ahmad Lone ^*

, Mudasir Ahmad Khan

, Bashir Ahmad Shah

Department of Anatomy, Govt. Medical College, Anantnag, Jammu and Kashmir, India , PARVAIZGULL01@GMAIL.COM

Abstract: (107 Views)

Background Nandrolone decanoate is a widely abused synthetic anabolic-androgenic steroid associated with prostate disorders in users. This study quantitatively analyzes its morphometric and histopathological effects on rat prostate tissue.
Methods Twenty male Wistar albino rats were divided into control (Group A, n=5) and treatment (Group B, n=15) groups. Group A received weekly intramuscular injections of peanut oil vehicle, while Group B received nandrolone decanoate (10 mg/kg body weight) weekly for 8 weeks. Body weights were recorded weekly. After euthanasia, prostate tissues were weighed and processed for histological examination using hematoxylin and eosin staining. Data are presented as mean ± standard deviation. Statistical significance was determined using an unpaired Student’s t-test for weight measurements and Fisher’s exact test for incidence rates (p < 0.05 considered significant).
Results Nandrolone administration significantly increased final body weight in treated animals (Group B: 345.5 ± 15.2 g) compared to the control (Group A: 305.8 ± 12.4 g; p = 0.003). Prostate weight was markedly higher in Group B (1.50 ± 0.20 g) than in Group A (0.95 ± 0.10 g; p < 0.001). Histopathological analysis showed normal prostate architecture in all control animals (100%, 5/5), while all treated rats (100%, 15/15; p < 0.001) developed benign prostatic hyperplasia. Specific lesions in Group B included stromal fatty adhesion (73.3%, 11/15; p = 0.007) and intra-glandular bleeding (40%, 6/15; p = 0.028).
Conclusion Nandrolonedecanoate induces significant increases in body weight (13%) and prostate weight (58%), and causes a high incidence of histopathological abnormalities, including benign prostatic hyperplasia. These findings demonstrate its potent androgenic effects and substantial risk for prostatic pathology.

Keywords: Albino rats, Anabolic steroids, Nandrolonedecanoate, Prostate

Full-Text [PDF 547 kb] (63 Downloads)

Type of Study: orginal article | Subject: General

References

1. Bahrke MS, Yesalis CE, Brower KJ. Anabolic-androgenic steroid abuse and performance-enhancing drugs among adolescents. Child Adolesc Psychiatr Clin N Am. 1998;7(4):821-38. [DOI:10.1016/S1056-4993(18)30214-1] [PMID]

2. Birgner C, Kindlundh-Högberg AM, Oreland L, Alsiö J, Lindblom J, Schiöth HB, et al. Reduced activity of monoamine oxidase in the rat brain following repeated nandrolone decanoate administration. Brain Res. 2008;1219:103-10. [DOI:10.1016/j.brainres.2008.05.014]

3. Gooren L. Osteoporosis and sex steroids. The Journal of Men's Health and Gender. 2007;4(2):192-8. [DOI:10.1016/j.jmhg.2007.03.003]

4. Mudali S, Dobs AS. Effects of testosterone on body composition of the aging male. Mech Ageing Dev. 2004;125(4):297-304. [DOI:10.1016/j.mad.2004.01.004]

5. Seal LJ. Testosterone replacement therapy. Medicine. 2009;37(9):445-9. [DOI:10.1016/j.mpmed.2009.06.002]

6. Maravelias C, Dona A, Stefanidou M, Spiliopoulou C. Adverse effects of anabolic steroids in athletes. A constant threat. Toxicology Lett. 2005;158(3):167-75. [DOI:10.1016/j.toxlet.2005.06.005] [PMID]

7. Brower KJ. Anabolic steroid abuse and dependence. Curr Psychiatry Rep. 2002;4(5):377-87. [DOI:10.1007/s11920-002-0086-6]

8. Tahtamouni LH, Mustafa NH, Hassan IM, Ahmad IM, Yasina SR, Abdallaa MY. Nandrolone decanoate administration to male rats induces oxidative stress, seminiferous tubules abnormalities, and sperm DNA fragmentation. Jordan Journal of Biological Sciences. 2010;3(4):165-74. [URL]

9. Rahnema CD, Crosnoe LE, Kim ED. Designer steroids - over-the-counter supplements and their androgenic component: review of an increasing problem. Andrology. 2015;3(2):150-5. [DOI:10.1111/andr.307]

10. Kanayama G, Hudson JI, DeLuca J, Isaacs S, Baggish A, Weiner R, et al. Prolonged hypogonadism in males following withdrawal from anabolic-androgenic steroids: an under-recognized problem. Addiction. 2015;110(5):823-31. [DOI:10.1111/add.12850] [PMID]

11. Modlinski R, Fields KB. The effect of anabolic steroids on the gastrointestinal system, kidneys, and adrenal glands. Curr Sports Med Rep. 2006;5(2):104-9. [DOI:10.1097/01.CSMR.0000306529.74500.f6]

12. Basaria S, Wahlstrom JT, Dobs AS. Clinical review 138: Anabolic-androgenic steroid therapy in the treatment of chronic diseases. J Clin Endocrinol Metab. 2001;86(11):5108-17. [DOI:10.1210/jcem.86.11.7983] [PMID]

13. Ergün O, Koşar PA, Onaran İ, Darici H, Koşar A. Lysozyme gene treatment in testosterone induced benign prostate hyperplasia rat model and comparasion of its' effectiveness with botulinum toxin injection. International Braz J Urol. 2017;43(6):1167-75. [DOI:10.1590/s1677-5538.ibju.2016.0677]

14. Kim J, Yanagihara Y, Kikugawa T, Ji M, Tanji N, Masayoshi Y, et al. A signaling network in phenylephrine-induced benign prostatic hyperplasia. Endocrinology. 2009;150(8):3576-83. [DOI:10.1210/en.2008-1782] [PMCID]

15. Foster CS. Pathology of benign prostatic hyperplasia. Prostate Suppl. 2000;9:4-14. https://doi.org/10.1002/1097-0045(2000)45:9+<4::AID-PROS3>3.0.CO;2-Q [DOI:10.1002/1097-0045(2000)45:9+3.0.CO;2-Q] [PMID]

16. Karbalay-Doust S, Noorafshan A. Stereological study of the effects of nandrolone decanoate on the rat prostate. Micron. 2006;37(7):617-23. [DOI:10.1016/j.micron.2006.02.005] [PMID]

17. Crawford ED, Hirst K, Kusek JW, Donnell RF, Kaplan SA, McVary KT, et al. Effects of 100 and 300 units of onabotulinum toxin A on lower urinary tract symptoms of benign prostatic hyperplasia: a phase II randomized clinical trial. J Urol. 2011;186(3):965-70. [DOI:10.1016/j.juro.2011.04.062]

18. Arnouk R, Suzuki Bellucci CH, Benatuil Stull R, de Bessa J, Jr., Malave CA, Mendes Gomes C. Botulinum neurotoxin type A for the treatment of benign prostatic hyperplasia: randomized study comparing two doses. ScientificWorldJournal. 2012;2012:463574. [DOI:10.1100/2012/463574]

19. Gaschler MM, Stockwell BR. Lipid peroxidation in cell death. Biochem Biophys Res Commun. 2017;482(3):419-25. [DOI:10.1016/j.bbrc.2016.10.086] [PMCID]